

## Justin D. D'Aloia

Partner

New York | Securities Litigation

[jdaloia@pomlaw.com](mailto:jdaloia@pomlaw.com)



Justin D. D'Aloia represents clients in securities class action litigation. He has extensive experience litigating high-profile cases in federal and state courts across the United States against companies that operate in the financial services, life sciences, real estate, technology, and retail industries. His practice covers the full spectrum of proceedings, from pre-suit demand through settlement.

Justin recently helped win a \$10.5 million settlement with biotechnology company Immunity Bio for investors who said the company misled them about the likelihood of U.S. FDA approval of its bladder cancer drug.

Before joining Pomerantz, Justin was counsel at a large international law firm, where he focused on securities litigation and other complex shareholder class action litigation. He previously served as a law clerk to Judge Mark Falk of the United States District Court for the District of New Jersey.

Justin has received awards for his commitment to pro bono service, including the considerable hours he spent representing a wrongfully convicted man during special proceedings held in connection with his exoneration.

While studying at Fordham University School of Law, Justin was the editor-in-chief of the *Fordham International Law Journal*.

### EDUCATION

- Fordham University School of Law
- Juris Doctor
- Rutgers University
- Bachelor of Science, Economics

### ADMISSIONS

- New York
- United States District Courts for the District of Colorado
- United States District Courts for the Southern and Eastern Districts of New York
- United States District Courts for the Northern District of Texas
- United States Courts of Appeals for the Second, Third, Fifth, and Tenth Circuits

## Publications

- “Pomerantz Secures Important Win in Case Against B. Riley Financial”, *The Pomerantz Monitor*, Vol 23, Issue 1, March/April 2026
- “Pomerantz Secures \$10.5 Million Settlement for ImmunityBio Investors”, *The Pomerantz Monitor*, Vol. 22, Issue 4, July/August 2025
- “Goldman Sachs Cert Redux,” *The Pomerantz Monitor*, Vol. 20, Issue 5, September/October 2023

## Accolades

- *Benchmark Litigation* “40 & Under” List (2024-2025)
- *Lawdragon* Leading Plaintiff Financial Lawyer (2019-2026)
- *Super Lawyers*® “Top-Rated” Securities Litigation Attorney” (2016-2025)
- *Martindale-Hubbell AV*® *Preeminent*™ *Peer-Rated Attorney* (2014-2025)
- *American Lawyer* Top Rated Litigator (2023)
- *Benchmark Litigation* Star (2021-2023)
- *Northeast Trailblazer* (2021)
- *Legal 500* Recommended Securities Litigator (2016, 2021)